Ten years of anti-vascular endothelial growth factor therapy.
about
Cancer Transcriptome Dataset Analysis: Comparing Methods of Pathway and Gene Regulatory Network-Based Cluster Identification.Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells.Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitroDiscovery of pan-VEGF inhibitory peptides directed to the extracellular ligand-binding domains of the VEGF receptors.Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis.Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico InvestigationPDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently.Aptamers as targeted therapeutics: current potential and challenges.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).History and conceptual developments in vascular biology and angiogenesis research: a personal view.Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma.VEGF and Intraocular Neovascularization: From Discovery to Therapy.Modulation of VEGF receptor 2 signaling by protein phosphatases.Determinants of metastatic competency in colorectal cancer.Immunomodulatory Nanomedicine.Therapeutic targeting of the angiopoietin-TIE pathway.VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Tumor angiogenesis revisited: Regulators and clinical implications.The dark side of browning.Epithelial-to-Pericyte Transition in Cancer.Microenvironmental regulation of tumour angiogenesis.Molecular genetics and targeted therapy of WNT-related human diseases (Review).Resistance to metronomic chemotherapy and ways to overcome it.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Methylseleninic Acid Provided at Nutritional Selenium Levels Inhibits Angiogenesis by Down-regulating Integrin β3 SignalingCellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases.Normalizing Tumoral Vessels to Treat Cancer: An Out-of-the-Box Strategy Involving TIE2 Pathway.Simple and complex retinal dystrophies are associated with profoundly different disease networksThe potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies.Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers.Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors.Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor-α.
P2860
Q33569864-270C0B70-D9DB-4B37-809D-C7DA804BB66BQ36273980-168C3639-BB26-4631-A093-0FB361ACBC7EQ36890872-CDC0955E-7AAE-4BFF-8EAB-070F33A46077Q37168985-E5BD769F-22E1-4DE1-A2F0-9C58016740FFQ37388064-B1F8DD23-6047-4867-9DC9-2C13AD7BABD0Q37579627-93F23628-A45A-4FEB-9BC9-0A92C08729C8Q37625434-E83DAF11-BA47-4317-9BDA-DB667010BD50Q37718460-70D01AA1-02D3-4497-83C3-2D7CD8E00C41Q38290290-7B1EED50-080B-4344-A1A6-4B0BC5B5B4ACQ38645097-323AAC13-BC71-458C-9A71-738CED6B2422Q38652259-B9D13E9E-B190-42A0-8637-AAA4AAC51CD0Q38692304-05A69CBB-F673-49C9-9FE6-E7BB0393C666Q38707904-C8732041-16B9-4DF4-9DAE-A4B071BD2BEEQ38749030-D3182963-49FA-4CB9-86B9-8C9320708724Q38924081-C5295134-01A0-4FFF-A802-F61744C84822Q38978319-17B5D6A8-A63E-4C4E-8C03-5DF7F26F7149Q39020269-F59029E2-06CA-4425-A00D-B05BDA9FCDE3Q39085740-C061C1BF-0E80-4648-AE7E-78568CB20694Q39224331-14C69221-31A6-4BE8-8072-AFF0E07BA5C3Q39321127-DE601706-8E0E-4ABE-8C08-568D3E35E954Q39378135-C79ED63C-8316-4DB8-B83F-50C30D1E4858Q39393740-01ED112F-C0C0-4A13-917D-CE39948C2713Q39414477-F9E5E648-606D-4997-85B9-85A6D5D01C63Q39414887-C7704B0D-7DE2-4985-9079-C1808A6092C5Q39433862-2BE7F0FD-30FB-4180-942A-FC64560ED16AQ39450241-5A689D16-8A37-4ACD-A8F9-593F37B1F830Q40448516-D673B83B-D016-4574-BBEC-56AFD460DBCCQ41369903-067F59E3-2A39-4336-A856-E7F13AEF9C21Q41534532-8BFAD240-22B7-4A43-A698-55DD53476EFCQ41572871-8999A39F-8B0C-46B5-B037-EA60AC5B423CQ41710508-F3644F01-77A9-4416-90B1-6A173A5F0DB1Q41852634-2EC294C8-CDFF-451B-B2CD-AC1F14A09D6FQ42370368-209F988A-AE71-44B8-B96A-F40B3B27C2BCQ42371554-3B8294A1-DA01-413C-AB45-EDA2C85D8F23Q42644178-BDE026AE-C534-4F63-BCEC-0F7A8EC732BBQ45265302-30F0CCF2-A3B7-475C-A776-E636DA40AB1EQ46016818-358DDB4B-E1DD-45C8-B97F-8CCF86C7F95DQ47099537-8031B195-7013-495A-AC7B-C1B725EA49FDQ47104301-AEB782DA-E108-419E-A235-B94533BA3CBAQ47142939-62858FFD-CC75-41E3-8348-5B4D0DA85410
P2860
Ten years of anti-vascular endothelial growth factor therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Ten years of anti-vascular endothelial growth factor therapy.
@en
Ten years of anti-vascular endothelial growth factor therapy.
@nl
type
label
Ten years of anti-vascular endothelial growth factor therapy.
@en
Ten years of anti-vascular endothelial growth factor therapy.
@nl
prefLabel
Ten years of anti-vascular endothelial growth factor therapy.
@en
Ten years of anti-vascular endothelial growth factor therapy.
@nl
P2860
P356
P1476
Ten years of anti-vascular endothelial growth factor therapy.
@en
P2093
Anthony P Adamis
Napoleone Ferrara
P2860
P2888
P304
P356
10.1038/NRD.2015.17
P577
2016-01-18T00:00:00Z